Clinical recruitment conditions for Erdafitinib

The recruitment conditions for clinical trials of Erdafitinib (Erdafitinib) are to ensure clear objectives of the study, high comparability of data, and to protect the safety and rights of patients. The following are general recruitment conditions. Specific conditions may be adjusted due to differences in research design, trial purpose, etc.:

1. Disease status and type: Advanced or metastatic urothelial carcinoma (UC): Recruited patients generally need to be diagnosed with advanced or metastatic urothelial carcinoma to ensure study consistency and accuracy of targeting.

2. FGFRgene abnormalities: FGFRgene mutations or activation: Erdafitinib is mainly a therapeutic drug targeting FGFRgene abnormalities, so recruitment conditions usually require the presence of FGFRgene mutations or activation in the patient’s tumor tissue.

3. Treatment history: Previous treatment records: Some clinical trials may require that patients have not received a specific type of treatment before enrollment, or limit the type and amount of treatment previously received to ensure the purity of the research results.

4. Physical Condition: General Physical Condition: The patient's overall physical condition needs to be good enough to withstand the effects of treatment. Some tests may have specific requirements for blood routine, liver function, kidney function, etc.

5. Cardiovascular health: Cardiovascular status: Because some adverse effects of erdafitinib may be cardiovascular-related, patients' cardiovascular health may be part of the recruitment criteria.

6. Other gene testing: Other genetic variations: In addition to the detection of the FGFR gene, the test may also detect other genetic variations to gain a more comprehensive understanding of the patient's molecular characteristics.

7. Age and Gender: Age and Gender Requirements: Some trials may have specific requirements for patient age and gender to ensure sample consistency or to meet the special purpose of the study.

8. Capacity and Consent: Mental and Physical Ability: Patients need to have sufficient mental and physical ability to understand and cooperate with the requirements of the trial.

Informed consent: Patients participating in a trial are usually required to sign an informed consent form detailing the purpose, process, possible risks and benefits of the trial and other information.

9. Exclusion criteria: Failure to meet specific criteria: Trials usually stipulate some exclusion criteria, such as other serious diseases, history of allergies to specific drugs, etc., to ensure that the inclusion of patients meets the research objectives of the trial.

10. Follow-up and data collection: Follow-up ability: Since clinical trials usually require patients to participate for a period of time, patients need to have the ability to follow-up, including being able to receive regular follow-up and testing according to the research plan.

These recruitment conditions are set up to ensure the scientific nature of the trial and the safety of the patients. At the same time, we hope to use these conditions to screen out patients who are suitable for participating in the trial as much as possible to improve the reliability and validity of the study. If patients are interested in participating in a clinical trial, they should read the recruitment conditions carefully to understand whether they meet the requirements, and consult a professional doctor for more detailed information.

Erdafitinib is not currently available in the country, so patients cannot purchase it domestically and need to purchase erdafitinib through foreign channels. The original drug of erdafitinib is mainly the Hong Kong version of the original drug, with a price of more than 20,000, and needs to be purchased through a Hong Kong pharmacy. The generic drugs are relatively cheaper, mainly the Laos version and the Bangladesh Yaopin International version, with a price of about 1,000 to 2,000, and the ingredients of the original drug and the generic drug are basically the same.